Delhi-based Dr Dangs selected as central lab for Covaxin human clinical trials

By: |
July 23, 2020 4:14 PM

The vaccine is being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

This is a "randomised, double blind, placebo controlled multi-centric clinical trial in India", it added. This is a “randomised, double blind, placebo controlled multi-centric clinical trial in India”, it added.

A Delhi-based private laboratory has claimed that it has been selected as the central lab for human clinical trials of Covaxin, India’s indigenous COVID-19 vaccine candidate. The vaccine is being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

Dr. Dangs Lab said on Wednesday that it has partnered with Bharat Biotech for conducting the trials. “We are extremely privileged to announce that Dr. Dangs Lab, New Delhi has been provided the opportunity to serve the nation by being selected as the central lab for the Human Clinical trials of Covaxin; India’s indigenous COVID-19 vaccine being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV),” it said in a statement.

This is a “randomised, double blind, placebo controlled multi-centric clinical trial in India”, it added. “Dr. Dangs Lab is currently processing all samples for screening and safety for the various phases of this clinical trial, whereas all the efficacy studies will be performed in NIV (Pune),” the statement said.

The lab has already started receiving samples from 50 to 100 subjects per day from various trial sites for safety testing and will be increasing operations as per assigned timelines to cover 12 sites across the length and breadth of the country over this month, it added.

“Stringent quality norms driven by good clinical laboratory practice (GCLP) guidelines are being followed as mandated by regulatory authorities. The lab has renowned experts in each field who are working tirelessly and collectively to provide quality and timely results to fulfil the imminent need of an effective and safe COVID19 vaccine,” the statement said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Serum Institute says vaccine viable even at 60% to 70% efficacy
2After dip, labs look at increase in demand for RT-PCR tests again
3Night curfew to be clamped in Delhi due to rising Covid-19 cases? Here’s what AAP govt told High Court